Comparative Pharmacology
Head-to-head clinical analysis: DYNABAC versus ERY TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNABAC versus ERY TAB.
DYNABAC vs ERY-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dirithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, specifically to the 23S rRNA, inhibiting peptide chain elongation by blocking the translocation step. It also interferes with the assembly of the 50S ribosomal subunit. This action is primarily bacteriostatic but can be bactericidal at higher concentrations.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
500 mg orally once daily or 250 mg orally twice daily; usual duration 5-14 days depending on infection
250-500 mg orally every 6 hours or 333-666 mg every 8 hours. Maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults with normal renal function; may extend to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life of erythromycin base is approximately 1.5-2 hours in patients with normal renal function. In patients with end-stage renal disease, the half-life may be prolonged to 4-6 hours. The half-life is not significantly altered in hepatic impairment, but accumulation can occur with severe liver disease.
Approximately 65% of a dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; about 15% is excreted unchanged in the bile; fecal elimination accounts for <5%.
Erythromycin is primarily excreted in bile as active drug and metabolites, with approximately 12-15% of an administered dose excreted unchanged in urine. Fecal elimination accounts for about 30-60% of the dose, largely due to biliary excretion.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic